Dianthus Therapeutics, Inc. /DE/: Pay

Dianthus Therapeutics, Inc. /DE/ paid its 3 named executives $20.9M in total in FY2025 (Dec). CEO Marino Garcia was paid $10.6M of that.

Pay$100 in the stock at the end of FY22 → $652
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Marino GarciaPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Simrat Randhawa, M.D.Executive Vice President, Head of Research and Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Ryan SavitzExecutive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $7.7M. The CEO of Dianthus Therapeutics, Inc. /DE/ was paid $10.6M, 38% above the median.

  1. 1Dianthus Therapeutics, Inc. /DE/
  2. 2Disc Medicine
  3. 3Kymera Therapeutics
  4. 4Structure Therapeutics
  5. 5Vera Therapeutics
  6. 6Spyre Therapeutics
  7. 7Anaptysbio
  8. 84D Molecular Therapeutics, Inc.Not disclosed
  9. 9Annexon, Inc.Not disclosed
  10. 10Apogee Therapeutics, Inc.Not disclosed
  11. 11Astria Therapeutics, Inc.Not disclosed
  12. 12Aura BiosciencesNot disclosed
  13. 13Cabaletta Bio, Inc.Not disclosed
  14. 14Dyne TherapeuticsNot disclosed
  15. 15Edgewise TherapeuticsNot disclosed
  16. 16Inozyme Pharma, Inc.Not disclosed
  17. 17Kyverna Therapeutics, Inc.Not disclosed
  18. 18Longboard Pharmaceuticals, Inc.Not disclosed
  19. 19Pepgen Inc.Not disclosed
  20. 20Stoke TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.